SLC2A9 Gene Polymorphism Is Associated with Elevated Serum Uric Acid Caused by Pyrazinamide

Table 2

Genetic equilibrium status of SLC2A9, SLC22A12, and ABCG2.

SNP		Allele	HWE^a	MAF		MAF (1000 g-CHBS)^b
SLC2A9	rs1014290	A/G	0.367	0.364	G	0.385	G
	rs11722228	C/T	0.843	0.301	T	0.298	T
	rs13129697	T/G	0.734	0.427	G	0.466	G
SLC22A12	rs3825016	C/T	0.034	0.234	T	0.243	T
	rs475688	T/C	0.123	0.427	C	0.459	T
	rs7929627	A/G	0.287	0.381	G	0.428	G
	rs893006	C/A	0.034	0.234	A	0.243	A
ABCG2	rs2054576	A/G	1.000	0.203	G	0.231	G
	rs2231142	G/T	0.673	0.273	T	0.284	T
	rs2728109	A/C	0.456	0.213	A	0.224	A
	rs3114018	C/A	0.295	0.385	A	0.630	A

MAF, minor allele frequency. a, value of the Hardy–Weinberg equilibrium test; b, MAF of 1000 Genomes Project (Han Chinese in Beijing, China). Although unbalanced in the overall sample, they were normally distributed in the low-risk and high-risk groups (both and ).